A Look At Payers' Early Game Plans For Driving Biosimilar Use
Executive Summary
Interviews with US payers suggest that at first they are more likely to focus on promoting biosimilars in treatment-naïve patients, as opposed to switching those on branded drugs, according to a new Datamonitor report.
You may also be interested in...
Zarxio Coverage On Par With Innovators Even Without Interchangeable Designation
Avalere survey suggests payers are comfortable with covering the biosimilar but not necessarily actively promoting it over Neupogen or other competing brands.
Zarxio Coverage On Par With Innovators Even Without Interchangeable Designation
Avalere survey suggests payers are comfortable with covering the biosimilar but not necessarily actively promoting it over Neupogen or other competing brands.
Ringside For Zarxio At Supreme Court: Biosimilar Stakeholders Line Up
High court set to determine timing of biosimilar marketing and how parties handle patent disputes in Sandoz v. Amgen. Stakeholders say the outcome will impact innovation, access to biosimilars and future litigation.